# Dr. Lal PathLabs (LALPATHLAB) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/lalpathlab

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,969.5
- Change: +0.14%
- As of: 2026-11-06
- 1D return: +0.14%
- 5D return: +3.31%
- 1M return: +3.72%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

LALPATHLAB (₹1969.50) is trading in a bullish technical structure across daily, weekly, and monthly horizons, with price positioned above all key moving averages and the Supertrend indicator. The stock has rallied +30.4% year-to-date and sits near the upper end of its 252-day range (+88.3%), indicating strong relative strength but also proximity to resistance. A significant volume-driven upward anomaly on 2026-11-04 (+7.7% range, 3.19x volume ratio) suggests active participation, though the daily ADX of 20.37 indicates trend strength is currently developing rather than established. Immediate resistance lies at ₹1991.07 (pivot, +1.1%) and ₹1995.70 (high, +1.33%). Support is found at ₹1920.23 (-2.50%) and ₹1873.67 (-4.87%). While the weekly trend shows strong conviction (ADX 41.06), the daily momentum requires confirmation through sustained closes above the immediate pivot levels to validate further upside.

- Trend Structure: Bullish across all timeframes; price trades above EMA/SMA 20/50/200 and Supertrend indicators.
- Range Position: Trading near the top of its yearly range (+88.3% from low); immediate resistance at ₹1991.07 (+1.1%) and ₹1995.70 (+1.33%).
- Momentum & Participation: Daily trend strength is developing (ADX 20.37); recent extreme volume anomaly on 2026-11-04 supports active buying interest.
- Risk Metrics: Annualized volatility stands at +28.9%; current drawdown is -3.0% from highs; support levels at ₹1920.23 (-2.5%) and ₹1873.67 (-4.87%).

- Bullish Engulfing Reversal
- Morning Star
- Outside Bar
- Doji
- Inside Bar

### News Context

In the seven-day window ending 5 November 2026, Dr Lal PathLabs received multiple positive rating updates from brokerages following its second-quarter performance. Nomura raised its target price to ₹2,280 on 5 November, citing strong Q2 results and projecting a 12% upside potential. Antique Stock Broking also maintained a 'Buy' rating on the same date, highlighting strong revenue and profit growth as key drivers for the healthcare diagnostics firm. Additionally, Axis Securities included Dr Lalpath Labs in its Diwali 2026 technical stock picks on 2 November, assigning a buy rating with specific target prices among other equities expected to see up to 50% upside. Shriram Research similarly featured the company in its Diwali 2026 stock basket on 4 November, noting it as one of 11 recommended stocks with an average projected upside of approximately 19%. These coordinated analyst actions reflect confidence in the company's recent financial execution and underlying demand trends.

- Nomura raised its target price to ₹2,280 on 5 November 2026, citing strong Q2 performance and estimating a 12% upside potential.
- Antique Stock Broking maintained a 'Buy' rating on 5 November 2026, attributing the stance to strong revenue and profit growth.
- Axis Securities assigned a buy rating with specific target prices on 2 November 2026 as part of its Diwali 2026 technical stock picks.
- Shriram Research included Dr Lal PathLabs in its 11-stock Diwali 2026 basket on 4 November 2026, projecting an average upside of approximately 19%.

- [Nomura raises Dr Lal PathLabs target price to Rs 2,280 after strong Q2; sees 12% upside](https://www.moneycontrol.com/news/business/stocks/nomura-raises-dr-lal-pathlabs-target-price-to-rs-2-280-after-strong-q2-sees-12-upside-14071107.html)
- [BHEL, Clean Max, V-Mart Retail, Metropolis, EPL, Dr Lal PathLabs shares: Target prices](https://www.businesstoday.in/markets/stocks/story/bhel-clean-max-v-mart-retail-metropolis-epl-dr-lal-pathlabs-shares-target-prices-565804-2026-11-05)
- [Diwali 2026 stock picks: Shriram Research recommends 11 stocks with up to 32% upside](https://www.cnbctv18.com/photos/market/diwali-2026-stock-picks-shriram-research-recommends-11-stocks-with-up-to-32pc-upside-20027168.htm)
- [Diwali picks: HAL, Kotak Bank, TechM, Sona BLW, Auro Pharma among top picks for upto 50% upside](https://www.businesstoday.in/markets/stocks/story/diwali-picks-hal-kotak-bank-techm-sona-blw-auro-pharma-among-top-picks-for-upto-50-upside-565067-2026-11-02)
- [Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week](https://www.livemint.com/market/stock-market-news/cash-rewards-coming-pfc-concor-rites-pfc-to-sonata-these-firms-to-announce-dividend-with-q2-results-2026-this-week-11793537407103.html)

### What Changed

Dr. Lal Path Labs announced an interim dividend of Rs 5 per share on its equity shares, which have a face value of Rs 10. This corporate action was filed with the National Stock Exchange (NSE) on November 6, 2026. The record date for determining eligible shareholders is set for November 11, 2026. The filing does not specify distinct book-closure start and end dates, indicating that eligibility will be determined based on holdings recorded on the record date without a preceding suspension of trading for transfer purposes. This dividend represents a significant cash distribution to investors, effectively returning capital based on the company's current earnings or reserves.

- Interim dividend declared at Rs 5 per share against a face value of Rs 10.
- Record date established as November 11, 2026, for entitlement determination.
- Filing submitted to NSE on November 6, 2026, with no separate book-closure dates specified.

- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 5 PER SHARE |FACE VALUE:10 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)

### Official Filings

Dr. Lal Path Labs Ltd. announced key developments following its Board meeting on November 4, 2026, which approved unaudited financial results for the quarter and half-year ended September 30, 2026. The Board declared a second interim dividend of ₹5 per equity share (50% of the ₹10 face value), with a record date set for November 11, 2026. This follows an earlier interim dividend announcement filed on November 6, 2026.

Additionally, the Board appointed Ms. Vasuta Agarwal as an Additional Director designated as a Non-Executive Independent Director for three consecutive years starting November 4, 2026, subject to shareholder approval via postal ballot. The company also approved further investments totaling up to ₹49.5 crore in its wholly owned subsidiary, Dr. Lal PathLabs FZCO. Of this amount, up to ₹30 crore is allocated to Sunshine Healthcare Limited, Ghana, for business and operational requirements. These investments are proposed in cash, expected to be completed by March 31, 2027, or another mutually agreed date, and are stated to be related-party transactions conducted on an arm’s-length basis.

- Second Interim Dividend: Declared at ₹5 per share (50% of ₹10 face value); Record Date is November 11, 2026.
- Board Appointment: Ms. Vasuta Agarwal appointed as Additional Non-Executive Independent Director for three years from November 4, 2026, pending shareholder approval by postal ballot.
- Subsidiary Investment: Approved up to ₹49.5 crore investment in Dr. Lal PathLabs FZCO, including up to ₹30 crore for Sunshine Healthcare Limited, Ghana; completion expected by March 31, 2027.

- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 5 PER SHARE |FACE VALUE:10 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/LALPATHLAB_05112026122208_Newspaper05112026.pdf)
- [Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133338_BMoutcome041126.pdf)
- [Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026132659_BMoutcome041126.pdf)
- [Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on November 04, 2026, declared 2nd Interim Dividend of Rs. 5 per equity share. |SUBJECT: Dividend](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133122_BMoutcome041126.pdf)
- [Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133915_BMoutcome041126.pdf)
- [Dr. Lal Path Labs Ltd. has informed the Exchange that Record date for the purpose of 2nd Interim Dividend is 11-Nov-2026. |SUBJECT: Record Date](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133519_BMoutcome041126.pdf)
- [Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026134632_BMoutcome041126.pdf)

### Fundamentals

Dr. Lal Path Labs demonstrates robust operational momentum and improving financial health as of Q2 FY2026-27. Revenue from operations rose sequentially to ₹874 crore, driving Profit Before Tax (PBT) to ₹261 crore and Net Profit to ₹194 crore, with EPS increasing to ₹11.51. This quarterly acceleration aligns with a TTM sales growth of 14% and a 3-year compounded sales CAGR of 11%, supported by consistent profitability metrics including a 22% ROE over the last three years.

The balance sheet shows significant strengthening: cash and equivalents more than tripled to ₹344 crore by September 2026, while total assets grew to ₹3,458 crore. Equity base expanded sharply to ₹2,780 crore, likely reflecting capital raises or retained earnings accumulation, which has reduced reliance on borrowings despite recent fixed asset additions. Operating efficiency remains high, evidenced by a negative Cash Conversion Cycle (-79 days in Mar 2026) driven by strong payable days (123 days). Institutional interest is shifting, with DIIs increasing their stake to 21.57% while FIIs reduced holdings to 18.73% by September 2026. The key checkpoint is whether this sequential profit expansion sustains into full-year results, particularly given the rise in finance costs to ₹7 crore in Q2.

- Q2 FY2026-27 revenue reached ₹874 crore (+sequential), with Net Profit at ₹194 crore and EPS at ₹11.51, indicating strong margin execution.
- TTM sales growth stands at 14%, outpacing the 3-year CAGR of 11%, while ROE remains stable at 22%.
- Liquidity improved significantly; cash and equivalents rose to ₹344 crore (Sep 2026) from ₹116 crore (Sep 2025), supporting an equity base of ₹2,780 crore.
- DIIs increased holding to 21.57% (Sep 2026) vs FIIs' 18.73%, signaling a shift in institutional preference.

### Bull Case

Dr. Lal Path Labs presents a constructive case anchored by strong technical momentum and positive analyst sentiment, despite current price consolidation near resistance levels. As of November 6, 2026, the stock trades at ₹1,969.50, with market capitalization standing at approximately ₹33,012 crore. The technical structure shows bullish signals across multiple timeframes: the daily and monthly Supertrend indicators are both bullish, while the weekly ADI stands at 41.06, indicating strong trend strength. Year-to-date returns are +30.4%, and the one-year return is +26.7%, reflecting sustained investor interest.

On the fundamental side, Nomura has raised its target price to Rs 2,280 following strong Q2 performance, citing 12% upside potential. Antique Stock Broking maintains a 'Buy' rating, highlighting strong revenue and profit growth alongside healthy underlying demand. Axis Securities and Shriram Research have also included the stock in their positive outlooks for the period ahead. While the stock faces immediate resistance near ₹1,991–₹1,995, the combination of robust relative strength (Plus DI significantly higher than Minus DI on daily and weekly charts) and consistent brokerage support provides a conditional upside framework. Investors should monitor whether the stock can sustainably break above the ₹1,995 high to confirm further upward momentum.

- Technical Momentum: Daily, weekly, and monthly Supertrend indicators are bullish; weekly ADI is 41.06, signaling strong trend intensity.
- Analyst Sentiment: Nomura raised its target to Rs 2,280 (+12% upside); Antique Stock Broking maintains a 'Buy' rating citing strong revenue/profit growth and healthy demand.
- Price Action & Returns: Current price is ₹1,969.50 (Market Cap ~₹33,012 cr); YTD return is +30.4% and 1-year return is +26.7%.
- Resistance Levels: Immediate resistance sits at ₹1,991.07 (pivot) and ₹1,995.70 (high); a sustained break above these levels could validate further upside.

- [Nomura raises Dr Lal PathLabs target price to Rs 2,280 after strong Q2; sees 12% upside](https://www.moneycontrol.com/news/business/stocks/nomura-raises-dr-lal-pathlabs-target-price-to-rs-2-280-after-strong-q2-sees-12-upside-14071107.html)
- [BHEL, Clean Max, V-Mart Retail, Metropolis, EPL, Dr Lal PathLabs shares: Target prices](https://www.businesstoday.in/markets/stocks/story/bhel-clean-max-v-mart-retail-metropolis-epl-dr-lal-pathlabs-shares-target-prices-565804-2026-11-05)
- [Diwali 2026 stock picks: Shriram Research recommends 11 stocks with up to 32% upside](https://www.cnbctv18.com/photos/market/diwali-2026-stock-picks-shriram-research-recommends-11-stocks-with-up-to-32pc-upside-20027168.htm)
- [Diwali picks: HAL, Kotak Bank, TechM, Sona BLW, Auro Pharma among top picks for upto 50% upside](https://www.businesstoday.in/markets/stocks/story/diwali-picks-hal-kotak-bank-techm-sona-blw-auro-pharma-among-top-picks-for-upto-50-upside-565067-2026-11-02)
- [Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week](https://www.livemint.com/market/stock-market-news/cash-rewards-coming-pfc-concor-rites-pfc-to-sonata-these-firms-to-announce-dividend-with-q2-results-2026-this-week-11793537407103.html)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 5 PER SHARE |FACE VALUE:10 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/LALPATHLAB_05112026122208_Newspaper05112026.pdf)
- [Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133338_BMoutcome041126.pdf)
- [Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026132659_BMoutcome041126.pdf)
- [Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on November 04, 2026, declared 2nd Interim Dividend of Rs. 5 per equity share. |SUBJECT: Dividend](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133122_BMoutcome041126.pdf)

### FAQs

**What corporate actions has Dr. Lal PathLabs announced for November 2026?**

The board approved unaudited financial results for the quarter and half year ended September 30, 2026, on November 4, 2026. It declared a second interim dividend of INR 5 per equity share (face value INR 10), with a record date of November 11, 2026. Additionally, Ms. Vasuta Agarwal was appointed as an Additional Director, subject to shareholder approval.

**How is the stock performing technically as of November 6, 2026?**

The stock closed at ₹1,969.50, up +0.1% from the previous close. Technical indicators show a bullish trend across daily, weekly, and monthly timeframes. The nearest resistance levels are at ₹1,991.07 and ₹1,995.70, while support sits at ₹1,920.23. Year-to-date returns stand at +30.4%, with a one-year return of +26.7%.

**What investment views have brokerages expressed regarding Dr. Lal PathLabs?**

Nomura raised its target price to Rs 2,280, citing strong Q2 performance and seeing 12% upside potential. Antique Stock Broking maintained a 'Buy' rating, highlighting strong revenue and profit growth. Axis Securities also assigned a buy rating in its technical picks, noting positive momentum structures.

**Are there any significant capital allocation or expansion plans disclosed recently?**

Yes. The company approved further investment of up to INR 49.5 crore in its wholly owned subsidiary, Dr. Lal PathLabs FZCO. This includes up to INR 30 crore for its Ghana-based subsidiary, Sunshine Healthcare Limited. The investment is proposed in cash and is expected to be completed by March 31, 2027.

- [Nomura raises Dr Lal PathLabs target price to Rs 2,280 after strong Q2; sees 12% upside](https://www.moneycontrol.com/news/business/stocks/nomura-raises-dr-lal-pathlabs-target-price-to-rs-2-280-after-strong-q2-sees-12-upside-14071107.html)
- [BHEL, Clean Max, V-Mart Retail, Metropolis, EPL, Dr Lal PathLabs shares: Target prices](https://www.businesstoday.in/markets/stocks/story/bhel-clean-max-v-mart-retail-metropolis-epl-dr-lal-pathlabs-shares-target-prices-565804-2026-11-05)
- [Diwali 2026 stock picks: Shriram Research recommends 11 stocks with up to 32% upside](https://www.cnbctv18.com/photos/market/diwali-2026-stock-picks-shriram-research-recommends-11-stocks-with-up-to-32pc-upside-20027168.htm)
- [Diwali picks: HAL, Kotak Bank, TechM, Sona BLW, Auro Pharma among top picks for upto 50% upside](https://www.businesstoday.in/markets/stocks/story/diwali-picks-hal-kotak-bank-techm-sona-blw-auro-pharma-among-top-picks-for-upto-50-upside-565067-2026-11-02)
- [Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week](https://www.livemint.com/market/stock-market-news/cash-rewards-coming-pfc-concor-rites-pfc-to-sonata-these-firms-to-announce-dividend-with-q2-results-2026-this-week-11793537407103.html)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 5 PER SHARE |FACE VALUE:10 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/LALPATHLAB_05112026122208_Newspaper05112026.pdf)
- [Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133338_BMoutcome041126.pdf)
- [Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026132659_BMoutcome041126.pdf)
- [Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on November 04, 2026, declared 2nd Interim Dividend of Rs. 5 per equity share. |SUBJECT: Dividend](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133122_BMoutcome041126.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,991.07
- Risk regime: Price Risk Requires Attention

### Support levels
- 1865.38125
- 1611.7875
- 1551

### Resistance levels
- 1995.7
- 2033.1
- 2037.6333333333332

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.14% |
| return_10 | +7.14% |
| return_1m | +0.27% |
| return_1y | +26.74% |
| return_20 | +3.72% |
| return_3m | +2.15% |
| return_5 | +3.31% |
| return_6m | +24.16% |
| return_since_start | +29.02% |
| return_ytd | +30.45% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -25.48% |
| annualized_volatility | +28.93% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Dr. Lal Path Labs Ltd. Q2 FY2026-27: Revenue up 20% year on year

Revenue from operations rose 19.6% year on year to ₹873.9 crore in the quarter ended 30 September 2026, while profit for the period from continuing operations increased 27.5% to ₹194 crore. Sequentially, revenue grew 9.6% and profit rose 13.8%; basic EPS was ₹11.51, up from ₹10.15 in Q1 but below ₹18.05 a year earlier.

## Revenue and income

Revenue from operations increased from ₹730.6 crore in Q2 FY2025-26 and ₹797.7 crore in Q1 FY2026-27 to ₹873.9 crore in Q2 FY2026-27. Revenue has risen in each of the past three sequential quarters, from ₹659.8 crore in Q3 FY2025-26 to ₹702.7 crore in Q4, ₹797.7 crore in Q1 and ₹873.9 crore in Q2.

Including other income of ₹34.3 crore, total income was ₹908.2 crore, up 9.5% from ₹829.6 crore in Q1 FY2026-27.

## Expenses and profitability

Total expenses increased 7.8% sequentially to ₹647.6 crore, compared with 9.6% growth in revenue. Profit before tax rose 13.9% from ₹228.7 crore in Q1 to ₹260.6 crore in Q2, and was 28.0% higher than the ₹203.6 crore reported in Q2 FY2025-26.

Q2 expenses included ₹161.9 crore for materials, ₹138.6 crore for employee benefits, ₹46.9 crore of depreciation and amortisation, and ₹7 crore of finance costs.

## Tax and earnings

Tax expense was ₹66.6 crore, up from ₹58.2 crore in Q1 FY2026-27. Profit for the period from continuing operations rose 13.8% sequentially to ₹194 crore from ₹170.5 crore; it was up 27.5% year on year from ₹152.2 crore.

Basic EPS from continuing operations increased to ₹11.51 from ₹10.15 in Q1, while diluted EPS rose to ₹11.47 from ₹10.13. Both were lower than in Q2 FY2025-26, when basic and diluted EPS were ₹18.05 and ₹18.01, respectively. Trailing twelve-month EPS was ₹34.94. Of Q2 profit, ₹192.2 crore was attributable to owners of the parent and ₹1.7 crore to non-controlling interests.

## Cash generation and liquidity

Operating cash flow was ₹402.2 crore in Q2, against investing outflows of ₹134 crore, resulting in reported free cash flow of ₹268.2 crore. Financing outflows were ₹167.5 crore.

At 30 September 2026, cash and cash equivalents stood at ₹343.5 crore, current investments at ₹526.9 crore and bank balances other than cash equivalents at ₹736.4 crore. Together, these balances totalled ₹1,606.8 crore.

## Balance sheet

Total assets were ₹3,457.6 crore at 30 September 2026, up from ₹3,146 crore at 31 March 2026. Property, plant and equipment increased to ₹521.4 crore from ₹483.8 crore, and goodwill to ₹585.7 crore from ₹548.2 crore. Equity attributable to owners of the parent rose to ₹2,744.5 crore from ₹2,508.2 crore. Trade receivables were ₹141.3 crore, compared with ₹110.7 crore at 31 March.

## Key Takeaway

Q2 brought strong year-on-year growth in revenue and profit, with expenses rising more slowly than revenue sequentially. Cash generation remained substantial, while basic EPS was higher than Q1 but lower year on year; the quarter-end balance sheet also showed higher assets, equity and receivables than at 31 March 2026.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +52.93%
- FII holding: +18.73%
- DII holding: +21.57%
- Mutual fund holding: +18.68%
- Retail holding: +4.00%
- Promoter pledged: +0.00%

### Major reported shareholders

- Arvind  Lal — +29.91%
- Vandana  Lal — +19.16%
- HDFC MUTUAL FUND - HDFC NIFTY SMALLCAP 250 ETF — +3.91%
- SMALLCAP WORLD FUND, INC — +2.60%
- UTI-FLEXI CAP FUND — +2.49%
- ADITYA BIRLA SUN LIFE MUTUAL FUND - ADITYA BIRLA SUN LIFE SMALL CAP FUND — +2.19%
- NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA NIFTY 500 EQUAL WEIGHT INDEX FUND — +2.19%
- Anjaneya  Lal — +2.01%
- Archana Lal Erdmann — +1.84%
- SBI LARGE & MIDCAP FUND — +1.49%

## Official filings

- 2026-11-06 — Corporate Action Notice: Dr. Lal Path Labs Ltd. - Ex-Date: 11-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-06 — Corporate Action Notice: Dr. Lal Path Labs Ltd. - Ex-Date: 11-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-06 — Corporate Action Notice: Dr. Lal Path Labs Ltd. - Ex-Date: 11-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-05 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_05112026122208_Newspaper05112026.pdf)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133338_BMoutcome041126.pdf)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026132659_BMoutcome041126.pdf)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133122_BMoutcome041126.pdf)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133915_BMoutcome041126.pdf)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026133519_BMoutcome041126.pdf)
- 2026-11-04 — Management Change: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026134632_BMoutcome041126.pdf)
- 2026-11-04 — Press Release: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026141544_pressrelease.pdf)
- 2026-11-04 — Earnings Presentation: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026140847_investorpresentation.pdf)
- 2026-11-04 — Financial Results Filing: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752770_04112026053853_WEB.xml)
- 2026-11-04 — Financial Results Filing: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752767_04112026053836_WEB.xml)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/OUTCOME_13310_WebXMLFile_20261104_174207691.xml)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_13310_WebXMLFile_20261104_174853712.xml)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_13310_WebXMLFile_20261104_175138937.xml)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13310_WebXMLFile_20261104_181049353.xml)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04112026200529_Covering_AudioRecording_Signed.pdf)
- 2026-11-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13310_WebXMLFile_20261104_200904572.xml)
- 2026-10-27 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_27102026165710_concall.pdf)
- 2026-10-27 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13310_WebXMLFile_20261027_170340798.xml)
- 2026-10-27 — Board Meeting Notice: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13310_WebXMLFile_20261027_170340798.xml)
- 2026-10-27 — Board Meeting Notice: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_27102026164643_Dividend_Intimation.pdf)
- 2026-10-27 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13310_WebXMLFile_20261027_170642698.xml)

## News and market events

- 2026-11-07 — Mint: **Upcoming dividend, bonus, rights record date next week, 9-13 Nov: Dabur, RITES, CONCOR, HUL, ONGC, Emami among others** — At least 75 companies, including Dabur India, HUL, ONGC, and RITES, have fixed record dates for dividend, bonus, or rights issues between November 9 and 13, 2026. Dharti Proteins is the sole entity among these firms with a bonus issue record date on November 13, following its board's approval of a 1:1 ratio. Investors must hold shares before the respective record dates to qualify for these corporate actions. — [Source](https://www.livemint.com/market/stock-market-news/upcoming-dividend-bonus-rights-record-date-next-week-9-13-nov-dabur-rites-concor-hul-ongc-emami-among-others-11794037826095.html)
- 2026-11-05 — MONEYCONTROL: **Nomura raises Dr Lal PathLabs target price to Rs 2,280 after strong Q2; sees 12% upside** — Nomura has raised its target price for Dr Lal PathLabs to Rs 2,280 following the company's strong second-quarter performance. The brokerage firm sees a 12% upside potential in the stock based on this updated valuation. — [Source](https://www.moneycontrol.com/news/business/stocks/nomura-raises-dr-lal-pathlabs-target-price-to-rs-2-280-after-strong-q2-sees-12-upside-14071107.html)
- 2026-11-05 — BUSINESSTODAY: **BHEL, Clean Max, V-Mart Retail, Metropolis, EPL, Dr Lal PathLabs shares: Target prices** — Antique Stock Broking issued rating updates for six stocks following September-quarter results, maintaining 'Buy' ratings on Dr Lal PathLabs, Clean Max Enviro Energy Solutions, V-Mart Retail, BHEL, and EPL, while retaining a 'Hold' on Metropolis Healthcare. The brokerage cited strong revenue and profit growth, significant order wins for BHEL, and healthy underlying demand as key drivers, though it flagged input cost inflation as a risk for V-Mart Retail. — [Source](https://www.businesstoday.in/markets/stocks/story/bhel-clean-max-v-mart-retail-metropolis-epl-dr-lal-pathlabs-shares-target-prices-565804-2026-11-05)
- 2026-11-04 — CNBC-TV18: **Diwali 2026 stock picks: Shriram Research recommends 11 stocks with up to 32% upside** — Shriram Research has released a Diwali 2026 stock basket comprising 11 equities across banking, healthcare, consumer, industrial, and technology sectors, projecting an average upside potential of approximately 19% from November 2 closing prices. The recommendation highlights specific growth drivers for each company, such as Aeroflex’s data centre demand, ICICI Bank’s strong loan growth, and L&T’s record order inflows. This analysis provides investors with targeted insights into entities expected to benefit from sector-specific trends like liquid cooling, premiumisation, and EV exposure. — [Source](https://www.cnbctv18.com/photos/market/diwali-2026-stock-picks-shriram-research-recommends-11-stocks-with-up-to-32pc-upside-20027168.htm)
- 2026-11-02 — BUSINESSTODAY: **Diwali picks: HAL, Kotak Bank, TechM, Sona BLW, Auro Pharma among top picks for upto 50% upside** — Axis Securities presented technical stock picks for the year ahead, assigning buy ratings with specific target prices to multiple listed companies including Aurobindo Pharma Ltd, Hindustan Aeronautics Ltd, IOL Chemicals and Pharmaceuticals Ltd, Jyoti CNC Automation Ltd, Kotak Mahindra Bank Ltd, Karnataka Bank Ltd, Dr Lalpath Labs Ltd, Mayur Uniquoters Ltd, Shivalik Bimetal Controls Ltd, and Sona BLW Precision Forgings Ltd. The analysis also identified Tech Mahindra Ltd and Welspun Living Ltd as having positive momentum structures suggesting upside potential. — [Source](https://www.businesstoday.in/markets/stocks/story/diwali-picks-hal-kotak-bank-techm-sona-blw-auro-pharma-among-top-picks-for-upto-50-upside-565067-2026-11-02)
- 2026-11-01 — Mint: **Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week** — Multiple companies including Power Finance Corporation, Container Corporation of India Limited, RITES, and Sonata Software are scheduled to hold board meetings this week to announce Q2FY27 results and potentially approve dividends. — [Source](https://www.livemint.com/market/stock-market-news/cash-rewards-coming-pfc-concor-rites-pfc-to-sonata-these-firms-to-announce-dividend-with-q2-results-2026-this-week-11793537407103.html)
- 2026-10-30 — BUSINESSTODAY: **HAL, Kotak Bank, Tech Mahindra, Sona BLW Precision: Top Diwali 2026 Picks by Axis Securities** — Axis Securities issued Diwali 2026 technical buy recommendations for multiple Indian equities, citing breakout patterns and momentum indicators as drivers for potential upside. The broker identified specific support zones and target price ranges for stocks including Aurobindo Pharma, HAL, IOL Chemicals, Jyoti CNC Automation, Kotak Mahindra Bank, Karnataka Bank Limited, Dr. Lal Path Labs, Mayur Uniquoters, Shivalik Bimetal Controls, Welspun Living, Sona BLW Precision Forgings Limited, and Tech Mahindra. — [Source](https://www.businesstoday.in/markets/stocks/story/hal-kotak-bank-tech-mahindra-sona-blw-precision-top-diwali-2026-picks-by-axis-securities-564808-2026-10-30)
- 2026-10-14 — The Hindu: **Buzzing stocks: Watch out for these 16 stocks including Adani Enterprises, Polycab, ICICI Life Insurance, Aegis Logistics, RailTel,  Dr Lal Path, BEL** — 16 stocks in focus as Adani, ICICI Life Insurance, RailTel and others spark activity across AI ventures, M&A, approvals and expansions — [Source](https://www.thehindubusinessline.com/markets/buzzing-stocks-watch-out-for-these-16-stocks-including-adani-enterprises-polycab-icici-life-insurance-aegis-logistics-railtel-dr-lal-path-bel/article71582092.ece)
- 2026-09-29 — MONEYCONTROL: **Dr. Lal PathLabs builds defence against commodification** — opinion, MCPro, Dr LalPathlabs — [Source](https://www.moneycontrol.com/news/opinion/dr-lal-pathlabs-builds-defence-against-commodification-14040463.html)
- 2026-09-28 — Mint: **Dr Lal PathLabs adds genomics heft with SN Genelab deal** — SN Genelab’s testing capabilities could gain wider reach through Dr Lal's network over time, potentially boosting growth — [Source](https://www.livemint.com/market/mark-to-market/dr-lal-pathlabs-share-price-dr-lal-pathlabs-sn-genelab-deal-genomics-11790581986691.html)
- 2026-09-27 — The Hindu: **China’s consumer stocks trapped in a lost decade as AI boom dominates** — Weak spending, sluggish incomes and falling property prices are weighing on consumer companies as investors increasingly concentrate on technology stocks — [Source](https://www.thehindubusinessline.com/markets/stock-markets/chinas-consumer-stocks-trapped-in-a-lost-decade-as-ai-boom-dominates/article71515080.ece)
- 2026-09-26 — The Hindu: **Dr Lal PathLabs’ subsidiary acquires 80% stake in Ghana’s Sunshine Healthcare** — Dr Lal PathLabs’ Dubai subsidiary has completed the acquisition of an 80 per cent stake in Ghana-based Sunshine Healthcare Ltd. — [Source](https://www.thehindubusinessline.com/companies/dr-lal-pathlabs-arm-acquires-80-stake-in-ghanas-sunshine-healthcare/article71513963.ece)
- 2026-09-25 — Economic Times: **Stocks in news: Waaree Energies, PB Fintech, Lemon Tree Hotels and Dr Lal PathLabs** — Indian equity markets saw significant declines, with the NSE Nifty 50 index dropping by over 380 points. PB Fintech experienced a sharp 36% plunge after regulatory changes. Waaree Energies expanded into the specialty gases business to supply semiconductor manufacturers. Dr Lal PathLabs approved the acquisition of a majority stake in SN Genelab Private Ltd. Several companies, including JSW Cement, faced regulatory scrutiny amid ongoing market fluctuations. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-waaree-energies-pb-fintech-lemon-tree-hotels-and-dr-lal-pathlabs/articleshow/134467817.cms)
- 2026-09-25 — Mint: **Stock recommendations for 25 September from MarketSmith India** — MarketSmith India reveals its top stock recommendations for today, 25 September. Get expert insights into the best-performing stocks to guide your investment decisions. — [Source](https://www.livemint.com/market/stock-market-news/stock-recommendations-for-25-september-from-marketsmith-india-11790252543786.html)
- 2026-09-24 — CNBC-TV18: **Dr Lal PathLabs to acquire 70% stake in genomics firm SN Genelab for up to ₹168 crore** — Shares of Dr Lal PathLabs Ltd ended at ₹1,958.80, up by ₹36.20, or 1.88%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/dr-lal-pathlabs-share-price-to-acquire-70-stake-in-genomics-firm-sn-genelab-for-up-to-rs-168-crore-19997895.htm)
- 2026-09-16 — Mint: **Stock recommendations for 16 September from MarketSmith India** — MarketSmith India reveals its top stock recommendations for today, 16 September. Get expert insights into the best-performing stocks to guide your investment decisions. — [Source](https://www.livemint.com/market/stock-market-news/stock-recommendations-for-16-september-from-marketsmith-india-11789472199358.html)
- 2026-09-13 — BUSINESS: **Robust demand, pricing to keep volumes strong for diagnostics sector** — Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage — [Source](https://www.business-standard.com/markets/news/markets-news-robust-demand-pricing-to-keep-volumes-strong-for-diagnostics-126091300223_1.html)
- 2026-07-28 — Mint: **Raja Venkatraman recommends three stocks for 28 July | Stock Market News** — Market expert Raja Venkatraman shares his top stock picks for 28 July. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-28-july-11785153779486.html)
- 2026-07-27 — Economic Times: **Dr Lal PathLabs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?** — Dr Lal PathLabs shares surged after a strong Q1FY27 earnings beat, driven by higher realisations and price hikes. Brokerages including Nomura, Nuvama and JM Financial raised target prices, citing robust growth outlook, network expansion and improving margins, with continued momentum expected from diagnostics demand and strategic investments. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/dr-lal-path-labs-shares-soar-8-after-q1-earnings-beat-estimates-what-nomura-nuvama-other-brokerages-are-saying/articleshow/132652906.cms)
- 2026-07-15 — Mint: **Market strategy: Kotak Equities adds TCS, SBI Life Insurance in model portfolio, raises weight on L&T** — Market strategy: Both TCS and SBI Life have been assigned a weight of 150 basis points (bps) in the brokerage’s model portfolio. The brokerage, however, clarified that TCS's inclusion in the model portfolio should not be interpreted as a broader endorsement of the IT services sector. — [Source](https://www.livemint.com/market/stock-market-news/market-strategy-kotak-equities-adds-tcs-sbi-life-insurance-in-model-portfolio-raises-weight-on-l-and-t-11784106568903.html)

## Business profile

**Strategic vision:** Provider of diagnostic and related healthcare services.

### Business segments
- **Diagnostic and Healthcare Services:** Offers pathology services, operates a blood bank, and provides diagnostic testing through a network of clinical laboratories, patient service centers, and pick-up points.

### Competitive strengths
- Widespread domestic network of clinical laboratories, patient service centers, and pick-up points.
- International operations in multiple countries.
- Logistics strength supported by a network of satellite labs, staff, and doctors.
- NABL-accredited laboratories.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Anthem Biosciences Limited (Healthcare)](https://faxioms.com/stocks/anthem) — +0.16%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/lalpathlab
Markdown representation: https://faxioms.com/stocks/lalpathlab?render=md